A Phase 2 interventional study of BYM338 active drug and Placebo in Cachexia, sponsored by Novartis Pharmaceuticals. Completed at 10 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-02.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Cachexia with a site in United States — 9 open to participants now, 11 under way, 2 of them phase 3. Cachexia · United States.
Among the 95 studies in Cachexia with a site in United States, this one is the 31st largest by enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2011, is one of 24 in phase 2, and was the 46th registered.
331 studies on the registry are indexed under Cachexia; 74 are open to participants now.
Browse Cachexia studies →9 of the 95 studies in Cachexia with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
CatalYm GmbH · Sites in United States, Bulgaria, Czechia and 11 more countries
Ages 18+
Pfizer · Sites in United States, Australia, Belgium and 18 more countries
Ages 18+
Endevica Bio · Sites in United States, Canada
Ages 18+
University of Kansas Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 26 · Phase 3 20 · Phase 4 2
First in 1997; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 74 across 226 interventional studies indexed under Cachexia.
Median enrollment 51 across the 72 interventional studies, 36 across the 16 observational. Of the 82 that completed or were terminated, 28 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 95 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 4 studies filed under Cachexia — fewer than ten, so there is no comparison to draw.
4 of the studies in Cachexia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06721260University of Kansas Medical CenterMetabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS) | 2027-01 |
| NCT07146893University of OklahomaFeasibility Study for Repurposing RET Inhibitors | 2027-02-23 |
| NCT05705492OHSU Knight Cancer InstituteOlanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | 2027-06-30 |
| NCT06937177Endevica BioSafely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 95 studies in Cachexia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
Key Inclusion criteria:
Key Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BYM338 active drug
Drug: BYM338 active drug · Drug: Placebo
Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8
Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was no more than or equal to 2% at Week 8 was considered responders.
Time frame: Baseline, week 8
Percentage Change in Body Weight From Baseline at Week 7 and Week 9
Percentage Change in body weight from baseline in killograms (kg) at week 7 and week 9
Time frame: Baseline, Week 7 and Week 9
Maximum Observed Serum Concentration (Cmax)
Blood samples for pharmacokinetic (PK) evaluation were drawn on Day 1 30mg/kg BYM338 (Core)or week 8 Late 30mg/kg BYM338 (when placebo subjects were rolled over to active). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 1 and Week 8
Time to Reach the Maximum Concentration After Drug Administration (Tmax)
Blood samples for pharmacokinetic (PK) evaluation were drawn on Day 1 30mg/kg BYM338 (Core)or week 8 Late 30mg/kg BYM338 (when placebo subjects were rolled over to active). Tmax was directly determined from the raw serum concentration-time data.
Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 1 and Week 8
Percentage Change From Baseline in Total Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo: at Week 8
total lean body mass (LBM) is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(LBM at Visit - LBM at Baseline) / LBM at Baseline\] \* 100.
Time frame: Baseline, Week 8
Percentage Change From Baseline of Bone Mineral Density (BMD) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo at Week 8
Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.
Time frame: Baseline, Week 8
Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Number of Steps Taken Compared to Placebo at Week 4 and 7
Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.
Time frame: Baseline, Week 4 and Week 7
Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Sedentary Taken Compared to Placebo at Week 4 and 7
Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.
Time frame: Baseline, Week 4 and Week 7
Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Standing Compared to Placebo at Week 4 and 7
Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.
Time frame: Baseline, Week 4 and Week 7
Percentage Change From Baseline of Physical Activity Levels (Using the ActivPAL™ Device) Time Stepping Compared to Placebo at Week 4 and 7
Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.
Time frame: Baseline, Week 4 and Week 7
Core Phase single dose BYM338 30mg/kg i.v. active or placebo with 8week followup. Followup phase started Week 8 \& patients on placebo in the Core Phase were given BYM338 \& patients on BYM338 in Core Phase continued to be followed for an additional 8 weeks. Late BYM338 are patients who received Placebo during Core Phase and then BYM338 after Week 8.
| Milestone | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 |
|---|---|---|
| Started | 29 | 28 |
| Completed | 10 | 16 |
| Not completed | 19 | 12 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Death | 5 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Withdrawal by subject | 10 | 7 |
Thigh Muscle Volume (TMV) change was evaluated by a responder analysis. Patients whose loss of muscle TMV by MRI was no more than or equal to 2% at Week 8 was considered responders.
| Percentage Change of TMV | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 |
|---|---|---|
| Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8 | 2.0 ± 8.094 | 0.65 ± 8.239 |
Percentage Change in body weight from baseline in killograms (kg) at week 7 and week 9
| Percent Change of Weight (kg) | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 |
|---|---|---|
| Week 7 (n= 15, 17) | -3.3 ± 5.035 | -0.68 ± 4.457 |
| Week 9 (n=14,16) | -1.8 ± 7.131 | -0.32 ± 3.271 |
Blood samples for pharmacokinetic (PK) evaluation were drawn on Day 1 30mg/kg BYM338 (Core)or week 8 Late 30mg/kg BYM338 (when placebo subjects were rolled over to active). PK parameters were calculated from plasma concentration-time data using non-compartmental methods.
| ng/ml | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 |
|---|---|---|
| Maximum Observed Serum Concentration (Cmax) | 422 ± 142 | 408 ± 78.4 |
Blood samples for pharmacokinetic (PK) evaluation were drawn on Day 1 30mg/kg BYM338 (Core)or week 8 Late 30mg/kg BYM338 (when placebo subjects were rolled over to active). Tmax was directly determined from the raw serum concentration-time data.
| hr | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 |
|---|---|---|
| Time to Reach the Maximum Concentration After Drug Administration (Tmax) | 2.05 ± 142 | 2.22 ± 78.4 |
total lean body mass (LBM) is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(LBM at Visit - LBM at Baseline) / LBM at Baseline\] \* 100.
| Percentage Change in LBM | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 |
|---|---|---|
| Percentage Change From Baseline in Total Lean Body Mass (LBM) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo: at Week 8 | 4.97 ± 7.537 | 2.41 ± 4.625 |
Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.
| Percentage Change in BMD | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 |
|---|---|---|
| Percentage Change From Baseline of Bone Mineral Density (BMD) by Dual-Energy X-ray Absorptiometery (DXA) Compared to Placebo at Week 8 | 0.51 ± 3.712 | 0.14 ± 4.14 |
Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.
| percentage change in number of steps | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 |
|---|---|---|
| Week 4 (n=18, 23) | 917.78 ± 3720.491 | 63.59 ± 130.913 |
| Week 7 (n=13, 22) | -17.37 ± 80.350 | 35.80 ± 119.486 |
Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.
| percentage change in time (minutes) | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 |
|---|---|---|
| Week 4 (n=18, 23) | -0.05 ± 10.049 | 52.25 ± 207.403 |
| Week 7 (n=13, 22) | 107.85 ± 280.791 | 60.25 ± 222.366 |
Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.
| percentage change in time (minutes) | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 |
|---|---|---|
| Week 4 (n=18, 23) | 1.82 ± 78.364 | 38.17 ± 111.361 |
| Week 7 (n=13, 22) | 41.90 ± 251.291 | 23.76 ± 99.268 |
Each patient was required to wear the ActivPal™ for a span of 6 days at Week 4 and Week 7 for patient home activity recording. The ActivPal™ was given to patients in clinic to wear for 6 consecutive days. The ActivPAL™ records periods spent sitting, standing and walking, sit-to-stand transitions, step count and rate of stepping (cadence) over a maximum period of 10 days with a fully charged new battery.
| percentage change in time (minutes) | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 |
|---|---|---|
| Week 4 (n=18, 22) | 1446.69 ± 6011.324 | 85.30 ± 159.949 |
| Week 7 (n=13, 21) | -31.64 ± 67.180 | 33.39 ± 129.218 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Core - 30mg/kg BYM338 | — | 18/29 (62.1%) | 19/29 (65.5%) |
| Core - Placebo | — | 4/28 (14.3%) | 19/28 (67.9%) |
| Follow-up - 30mg/kg BYM338 | — | 7/19 (36.8%) | 12/19 (63.2%) |
| Follow-up - Placebo | — | 1/3 (33.3%) | 2/3 (66.7%) |
| Follow-up - 30mg/kg BYM338 Late | — | 7/21 (33.3%) | 13/21 (61.9%) |
| Event | Core - 30mg/kg BYM338 | Core - Placebo | Follow-up - 30mg/kg BYM338 | Follow-up - Placebo | Follow-up - 30mg/kg BYM338 Late |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/29 | 0/28 | 0/19 | 1/3 | 0/21 |
| VomitingGastrointestinal disorders | 0/29 | 0/28 | 0/19 | 1/3 | 0/21 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/29 | 0/28 | 3/19 | 0/3 | 1/21 |
| DehydrationMetabolism and nutrition disorders | 3/29 | 0/28 | 0/19 | 0/3 | 0/21 |
| AnaemiaBlood and lymphatic system disorders | 2/29 | 0/28 | 0/19 | 0/3 | 0/21 |
| Urinary tract infectionInfections and infestations | 2/29 | 0/28 | 0/19 | 0/3 | 0/21 |
| Deep vein thrombosisVascular disorders | 2/29 | 0/28 | 0/19 | 0/3 | 0/21 |
| DiplopiaEye disorders | 0/29 | 0/28 | 1/19 | 0/3 | 0/21 |
| Disease progressionGeneral disorders | 0/29 | 1/28 | 1/19 | 0/3 | 0/21 |
| InfectionInfections and infestations | 0/29 | 0/28 | 1/19 | 0/3 | 0/21 |
| Event | Core - 30mg/kg BYM338 | Core - Placebo | Follow-up - 30mg/kg BYM338 | Follow-up - Placebo | Follow-up - 30mg/kg BYM338 Late |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 4/29 | 6/28 | 2/19 | 1/3 | 3/21 |
| AscitesGastrointestinal disorders | 2/29 | 1/28 | 1/19 | 1/3 | 1/21 |
| ConstipationGastrointestinal disorders | 2/29 | 1/28 | 0/19 | 1/3 | 0/21 |
| DysphagiaGastrointestinal disorders | 0/29 | 1/28 | 0/19 | 1/3 | 1/21 |
| FatigueGeneral disorders | 6/29 | 3/28 | 4/19 | 1/3 | 1/21 |
| DizzinessNervous system disorders | 2/29 | 0/28 | 0/19 | 1/3 | 1/21 |
| ErythemaSkin and subcutaneous tissue disorders | 1/29 | 0/28 | 0/19 | 1/3 | 0/21 |
| DiarrhoeaGastrointestinal disorders | 5/29 | 3/28 | 1/19 | 0/3 | 5/21 |
| NauseaGastrointestinal disorders | 5/29 | 1/28 | 0/19 | 0/3 | 2/21 |
| VomitingGastrointestinal disorders | 4/29 | 1/28 | 0/19 | 0/3 | 2/21 |
| Age, Continuous(years) | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 | Total |
|---|---|---|---|
| Mean | 62.8 ± 10.17 | 61.5 ± 10.74 | 62.1 ± 10.38 |
| Sex: Female, Male(Participants) | 30mg/kg BYM338 | Placebo / Late 30mg/kg BYM338 | Total |
|---|---|---|---|
| Female | 9 | 6 | 15 |
| Male | 20 | 22 | 42 |
The record gives a start of Aug 2011, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimagrumab